375 related articles for article (PubMed ID: 26522272)
21. Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.
Bevier WC; Castorino KN; Axelrod C; Haroush G; Farfan CC; Shelton N; Nelson K; Spink LA; Liu H; Kerr D
Diabetes Care; 2022 Jan; 45(1):67-73. PubMed ID: 34716211
[TBL] [Abstract][Full Text] [Related]
22. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
23. [Effects of long-acting insulin degludec on type 2 diabetic hemodialysis patients with poor glycemic control].
Wada K; Wada Y; Tsuruoka S
Nihon Jinzo Gakkai Shi; 2015; 57(5):872-7. PubMed ID: 26387380
[TBL] [Abstract][Full Text] [Related]
24. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
[TBL] [Abstract][Full Text] [Related]
25. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
Ghosal S; Sinha B; Gangopadhyay KK
Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
27. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
[TBL] [Abstract][Full Text] [Related]
28. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
[TBL] [Abstract][Full Text] [Related]
29. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis.
Holmes RS; Crabtree E; McDonagh MS
Diabetes Obes Metab; 2019 Apr; 21(4):984-992. PubMed ID: 30552792
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
32. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
[TBL] [Abstract][Full Text] [Related]
33. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yang Y; Long C; Li T; Chen Q
Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
[TBL] [Abstract][Full Text] [Related]
34. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
Tentolouris N; Knudsen ST; Lapolla A; Wolden ML; Haldrup S; Schultes B
Adv Ther; 2019 May; 36(5):1201-1210. PubMed ID: 30879256
[TBL] [Abstract][Full Text] [Related]
35. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
[No Abstract] [Full Text] [Related]
36. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Kazda CM; Bue-Valleskey JM; Chien J; Zhang Q; Chigutsa E; Landschulz W; Wullenweber P; Haupt A; Dahl D
Diabetes Care; 2023 May; 46(5):1052-1059. PubMed ID: 36920867
[TBL] [Abstract][Full Text] [Related]
37. Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus.
Nakae R; Kusunoki Y; Katsuno T; Tokuda M; Akagami T; Murai K; Hamaguchi T; Miyagawa J; Namba M
Drugs R D; 2014 Jun; 14(2):133-8. PubMed ID: 24838615
[TBL] [Abstract][Full Text] [Related]
38. Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases.
Keller MF; Vestgaard M; Damm P; Mathiesen ER; Ringholm L
Diabetes Res Clin Pract; 2019 Jun; 152():58-64. PubMed ID: 31102682
[TBL] [Abstract][Full Text] [Related]
39. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.
Home PD; Meneghini L; Wendisch U; Ratner RE; Johansen T; Christensen TE; Jendle J; Roberts AP; Birkeland KI
Diabet Med; 2012 Jun; 29(6):716-20. PubMed ID: 22150786
[TBL] [Abstract][Full Text] [Related]
40. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
